Consultation Hotline
+1 (302) 618-8777
+1 (302) 618-8777
Current location：Home > Blogs > Industry News
Nova Biomedical Acquires NanoCellect to Strengthen Cell Line Development Capabilities
Strategic Acquisition Expands Single-Cell Analysis, Cell Sorting, and Bioprocessing Solutions for Biotechnology and Pharmaceutical Research
Nova Biomedical, a global leader in advanced diagnostic and laboratory technologies, has announced the acquisition of NanoCellect Biomedical, a company specializing in innovative single-cell analysis and cell sorting technologies. The strategic transaction represents a significant step in Nova Biomedical’s expansion into the rapidly growing fields of biotechnology, cell therapy, and biopharmaceutical development.
By integrating NanoCellect’s advanced microfluidic cell sorting platforms with Nova Biomedical’s established expertise in laboratory diagnostics and life science solutions, the combined organization aims to provide researchers with more powerful tools for cell line development, precision cell analysis, and next-generation bioprocessing applications.
Cell line development is a critical process in biopharmaceutical manufacturing, particularly for the production of recombinant proteins, monoclonal antibodies, vaccines, and advanced cell therapies. The ability to rapidly identify, isolate, and characterize high-performing individual cells directly impacts development timelines, product quality, and manufacturing efficiency.
NanoCellect has developed innovative single-cell sorting technologies designed to enable researchers to analyze and isolate individual cells with high precision. Its microfluidic-based platforms offer advantages including gentle cell handling, high recovery rates, and compatibility with sensitive biological samples.
Through the acquisition, Nova Biomedical will enhance its capabilities in:
Single-cell isolation and characterization
High-throughput cell screening
Cell line optimization
Bioprocess development
Precision cell therapy research
The integration of these technologies is expected to help biotechnology companies accelerate the discovery and development of new therapeutic products.
Nova Biomedical has built a strong reputation in laboratory diagnostics, blood analysis, and biotechnology instrumentation. The company develops analytical platforms used in hospitals, research institutions, and industrial laboratories worldwide.
NanoCellect’s expertise focuses on cell analysis solutions that enable researchers to understand biological systems at the single-cell level. Its technology platform provides researchers with greater control over cell populations, allowing them to identify rare cell types and select optimal candidates for further development.
The combination of Nova Biomedical’s global infrastructure and NanoCellect’s specialized technology creates opportunities for integrated solutions covering the entire cell development workflow, from early research through production optimization.
The global demand for cell and gene therapies continues to increase, driving the need for more advanced analytical tools. Traditional cell population analysis methods often provide limited information because biological samples contain diverse cell populations with different characteristics.
Single-cell technologies address this challenge by enabling detailed analysis of individual cells, including differences in:
Cell phenotype
Functional activity
Genetic characteristics
Growth behavior
Therapeutic potential
For researchers developing personalized medicine approaches, these capabilities are increasingly important.
Nova Biomedical’s acquisition of NanoCellect reflects the growing industry trend toward precision biology, where understanding individual cellular differences plays a central role in improving therapeutic development.
One of the major challenges in biopharmaceutical development is reducing the time required to identify optimal production cell lines. Conventional workflows may require extensive screening and multiple rounds of optimization.
NanoCellect’s cell sorting technologies can help simplify these processes by enabling:
Faster identification of high-producing cells
Improved selection accuracy
Reduced development cycles
Better consistency in cell populations
These advantages may contribute to increased productivity for pharmaceutical companies and biotechnology organizations.
The combined capabilities of Nova Biomedical and NanoCellect could provide customers with more complete solutions for research, process development, and quality improvement.
The acquisition demonstrates Nova Biomedical’s commitment to expanding beyond traditional diagnostic markets and investing in emerging life science technologies.
As biotechnology continues to evolve, laboratories increasingly require integrated platforms that combine automation, advanced analytics, and precise biological measurement. Strategic investments in technologies such as single-cell analysis and cell sorting allow companies to address the changing needs of modern research environments.
Nova Biomedical is expected to continue developing innovative solutions that support researchers working in areas including:
Pharmaceutical discovery
Biologics manufacturing
Cell therapy development
Synthetic biology
Precision medicine
The acquisition of NanoCellect comes at a time when the biotechnology industry is experiencing rapid growth in cell-based research applications. The demand for reliable, high-performance tools for cell characterization and selection is increasing across academic, pharmaceutical, and industrial laboratories.
By combining NanoCellect’s specialized technology with Nova Biomedical’s experience and global presence, the companies are positioned to deliver improved solutions for researchers worldwide.
The collaboration may also encourage further innovation in automated cell analysis, helping scientists overcome challenges associated with complex biological systems.
Nova Biomedical’s acquisition of NanoCellect represents an important milestone in strengthening its capabilities in cell line development and advanced biological analysis. By combining expertise in diagnostics, laboratory instrumentation, and single-cell technologies, the company aims to provide researchers with more efficient and precise tools for biotechnology innovation.
As the pharmaceutical and biotechnology industries continue moving toward personalized medicine and advanced therapies, technologies that enable accurate cell selection and characterization will become increasingly valuable. The integration of NanoCellect’s platforms into Nova Biomedical’s portfolio highlights the company’s long-term commitment to supporting the future of life science research and bioprocess development.